Tema ETFs’s Enliven Therapeutics ELVN Stock Holding History

Tema ETFs’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.73M	Buy	103,107 +42,413	+70%	+$2.31M	0.18%	113
2026 Q2	$3.08M	Buy	60,694 +17,638	+41%	+$749K	0.1%	146
2026 Q1	$1.69M	Buy	+43,056	New	+$1.19M	0.11%	165
2025 Q4	–	Sell	-40,314	Closed	-$825K	–	575
2025 Q3	$825K	Buy	40,314 +7,735	+24%	+$156K	0.07%	291
2025 Q2	$654K	Buy	32,579 +8,931	+38%	+$169K	0.17%	123
2025 Q1	$465K	Buy	+23,648	New	+$509K	0.14%	114

Other funds holding ELVN

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

FIA

FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Tema ETFs's ELVN Position: Q3 2026 in Review

Tema ETFs increased its Enliven Therapeutics (ELVN) stake by 70% in Q3 2026, buying an estimated $2.31M and bringing the position to 103,107 shares worth $4.73M. The position accounts for 0.18% of the portfolio, ranked #113.

Tema ETFs first reported a position in ELVN in Q1 2025 and has held it in 6 quarters since. 9 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

Tema ETFs held 103,107 shares of Enliven Therapeutics worth $4.73M as of Q3 2026.
Tema ETFs bought 42,413 Enliven Therapeutics shares in Q3 2026, an estimated $2.31M.
Enliven Therapeutics made up 0.18% of Tema ETFs's portfolio in Q3 2026, its #113 holding.
Tema ETFs first reported a position in Enliven Therapeutics in Q1 2025 and has held it in 6 quarters since.
9 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on Tema ETFs's 13F filing for Q3 2026, filed 16 Oct 2026.